ArticleJournal of oncology2021
Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China.
Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03047889 (A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
Who cites it
6 citing papers in PubMed.
- Independent Risk Factors and a New Nomogram for Predicting Breast Cancer Risk for Bone Metastasis in Chinese Women: A Retrospective Study with External Validation.Journal of clinical medicine · 2026Article
- Trastuzumab deruxtecan in advanced breast cancer: a real-world study of efficacy and safety in Chinese cohort with HER2-positive and HER2-low expression.Frontiers in oncology · 2026Article
- Ferroptosis-related differential gene expression and immune correlates in luminal a subtype breast cancer: a prognostic model approach.World journal of surgical oncology · 2025Article
- Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China.Frontiers in oncology · 2025Article
- Navigating the implementation gap for Trastuzumab's journey from health insurance to patient access: a preliminary study in a hospital in China.Global health research and policy · 2024Article
- Analysis of Breast Cancer Differences between China and Western Countries Based on Radiogenomics.Genes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo better understand the status of medical treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the differences between the Chinese and the international clinical practice.
methodsThis was a retrospective, nationwide, multicenter, epidemiological study of advanced breast cancer patients from China. Between January 01, 2012, and December 31, 2014, a total of 3649 patients, covering 7 geographic regions and 21 institutions, participated in this series of studies. HER2-positive breast cancer was selected among the group and adopted into this study. In comparison, we summarized the demographics and clinical characteristics of HER2-positive breast cancer from the Surveillance, Epidemiology, and End Results (SEER) database.
resultsA total of 918 patients diagnosed as HER2-positive breast cancer patients were included. The median age at diagnosis was 46 years (ranging, 23 to 78) with a single-peak incidence. The proportions of stages II-IV at diagnosis and distance metastasis in viscera were more than half of the participants. In comparison, the prevalence of estrogen or progesterone receptor-positive expression and luminalB subtype was relatively lower than that of the United States. The receipt of chemotherapy was fairly higher, while the usage of targeted therapy was seriously insufficient. Tumor size was in significantly positive associations with the duration of targeted therapy (Kendall's correlation coefficient = 0.3,
conclusionOur study suggested that HER2-positive breast cancer patients were characterized as a younger trend, a lower prevalence of hormonal receptor (HR)-positive expression, and less accessible to anti-HER2 targeted therapy with insufficient duration over the past few years in China. Concerted efforts should be exerted for promising survival benefits in the future. The trial registration number is https://clinicaltrials.gov/ct2/show/NCT03047889.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.